Table 2. Follow-up endpoints results in patients with CL treated with Sb^vor miltefosine.

Follow-up endpoints	Sbv	Miltefosine	P value
	N = 30	N = 60
End of Treatment	20 days	28 days
Apparent cure (%)	1 (3.3)	1 (1.7)	0.61
Failure (%)	29 (96.7)	59 (98.3)
Lost in follow-up (%)	0	0
2 months after treatment
Apparent cure (%)	18 (60.0)	49 (81.7)	0.03
Failure (%)	12 (40.0)	11 (18.3)
Lost in follow-up (%)	1	2
6 months after treatment
Definitive cure (%)	16 (53.3)	45 (75.0)	0.04
Clinical Failure (%)	14 (46.7)	15 (25.0)
Lost in follow-up (%)	1	2
95% CI of cure rate	35.5% to 71.2%	64.0% to 86.0%
Difference in cure rate and 95% CI	21.7% (0.08 to 42.7)